VANCOUVER, British Columbia / Feb 23, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About AbCellera Biologics Inc.
AbCellera searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
| Last Trade: | US$2.94 |
| Daily Change: | -0.09 -2.97 |
| Daily Volume: | 2,882,893 |
| Market Cap: | US$868.390M |
January 13, 2025 November 07, 2024 November 04, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
